On Friday, October 15, 2010, a federal jury in the United States District Court for the District of Oregon returned defense verdicts on all counts in favor of Segal McCambridge's client, a medical device manufacturer, and against each of 3 plaintiffs whose cases had been consolidated for trial. The plaintiffs sought between $11 million and $19 million in total damages for permanent, disabling shoulder injuries known as post-arthroscopic glenohumeral chondrolysis (PAGCL). All 3 plaintiffs claimed that they sustained PAGCL after infusion pumps manufactured by our client were used to infuse local anesthetics into their shoulders following arthroscopic surgeries they underwent in 2004.
The 9-person jury unanimously found that plaintiffs failed to prove that the pumps were defective, or that the pumps caused the plaintiffs' injuries, or that Segal McCambridge's client failed to warn of any risk of injury known to the medical or scientific community at the time of the plaintiffs' surgeries.
The case is the first in the ongoing nationwide infusion pump litigation to be tried by Segal McCambridge, and also the first to result in a defense verdict. The Segal McCambridge trial team was led by Jeffrey Singer and Mark Crane, along with co-counsel Lori Cohen of Greenberg Traurig, and supported by a team of attorneys, paralegals and staff from multiple Segal McCambridge offices.
Update 11/8/10: A more detailed release has been posted. Read it here.